Oxford Nanopore Technologies plc

Equities

ONT

GB00BP6S8Z30

Advanced Medical Equipment & Technology

Market Closed - London S.E. Other stock markets 16:35:18 24/05/2024 BST			5-day change	1st Jan Change
110.3 ^GBX	-0.72%		+1.94%	-47.02%

05-23	Oxford Nanopore Technologies plc Provides Updates to its Clinical Product Pipeline	CI
05-03	Jefferies cuts AJ Bell; Deutsche likes ConvaTec	AN

Oxford Nanopore Technologies Limited Appoints John O'higgins as Non-Executive Director

October 05, 2021 at 08:00 am

Johnson Matthey Plc announces that John O'Higgins, Senior Independent Director, is appointed as a non-executive director of Oxford Nanopore Technologies plc, which has been admitted to the London Stock Exchange with effect from . John joined the board of Oxford Nanopore Technologies plc in September 2019.

Latest news about Oxford Nanopore Technologies plc

Oxford Nanopore Technologies plc Provides Updates to its Clinical Product Pipeline	05-23	CI
Jefferies cuts AJ Bell; Deutsche likes ConvaTec	05-03	AN
Jefferies raises B&M to 'hold'	04-22	AN
EARNINGS: EPE Special "cautiously optimistic"; RTW Biotech NAV rises	04-02	AN
Kepler Cheuvreux likes Diageo; BofA lifts Man	03-14	AN
IP Group net asset value declines amid supply chain issues, inflation	03-13	AN
Transcript : Oxford Nanopore Technologies plc Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 09:00 AM	03-12
Oxford Nanopore Technologies Launches PromethION 2 Integrated into Open Early Access	03-07	CI
Good signals from central banks	03-07
Oxford Nanopore Technologies top team buys shares	03-07	AN
ANALYST RECOMMENDATIONS : AMD, Micron Technology, Snowflake, Zoom, Okta...	03-07
ITV, LondonMetric, Man, Domino's get upgrades	03-07	AN
What’s happening to the US economy?	03-06
Oxford Nanopore confident in future opportunities despite weak 2023	03-06	AN
ANALYST RECOMMENDATIONS : Crowdstrike, Target, Antofagasta, Direct Line Insurance, Premier Foods...	03-06
Shares rise in London ahead of budget	03-06
Oxford Nanopore Technologies' FY23 Loss Widens; Revenue Falls	03-06	MT
Transcript : Oxford Nanopore Technologies plc, Q4 2023 Earnings Call, Mar 06, 2024	03-06
ConvaTec profit doubles; DS smith trades in line	03-06	AN
Earnings Flash (ONT.L) OXFORD NANOPORE TECHNOLOGIES Reports FY23 Revenue GBP169.7M	03-06	MT
Earnings Flash (ONT.L) OXFORD NANOPORE TECHNOLOGIES Reports FY23 Loss GBX-19.00	03-06	MT
Oxford Nanopore Technologies plc Provides Earnings Guidance for the Year 2024	03-06	CI
Oxford Nanopore Technologies plc Reports Earnings Results for the Full Year Ended December 31, 2023	03-06	CI
EXECUTIVE CHANGES: Metro Bank names new CFO; Corre exec leaves	02-29	AN
Oxford Nanopore Technologies plc Announces Directorate Change	02-29	CI

Chart Oxford Nanopore Technologies plc

Duration

Period

More charts

Company Profile

Oxford Nanopore Technologies plc is engaged in the generation of molecular sensing technology based on nanopores. The Company has developed a deoxyribonucleic (DNA)/ ribonucleic acid (RNA) sequencing technology. The Companyâs segments include Life Science Research Tools, which offers products and services for research use, and COVID Testing, which provides products for SAR-Cov-2 testing. Its sequencing technology offers real-time analysis, in fully scalable formats from pocket to population scale, that can analyze native DNA or RNA and sequence any length of fragment to achieve short to ultra-long read lengths. Its products include MinION, GridION, PromethION, Flongle and others. MinION is a real-time device for DNA and RNA sequencing. GridION is a benchtop device designed to run and analyze up to five MinION or Flongle Flow Cells. Flongle is an adapter for MinION or GridION that enables direct, real-time DNA sequencing, or cDNA sequencing on smaller, single-use flow cells.

Sector

Advanced Medical Equipment & Technology

Calendar

10/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Oxford Nanopore Technologies plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.103 GBP

Average target price

1.98 GBP

Spread / Average Target

+79.51%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
OXFORD NANOPORE TECHNOLOGIES PLC	-47.02%	1.22B
THERMO FISHER SCIENTIFIC	+10.03%	223B
DANAHER CORPORATION	+13.59%	194B
INTUITIVE SURGICAL, INC.	+20.01%	141B
BOSTON SCIENTIFIC CORPORATION	+30.83%	109B
SIEMENS HEALTHINEERS AG	+2.05%	64.85B
EDWARDS LIFESCIENCES CORPORATION	+15.38%	52.7B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+3.96%	51.77B
AGILENT TECHNOLOGIES, INC.	+8.37%	44.12B
GE HEALTHCARE TECHNOLOGIES INC.	+3.27%	36.21B

Other Advanced Medical Equipment & Technology